Hosted on MSN5h
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says MizuhoMizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...
Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...
Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...
Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising Phase 2 results, Cybin’s PARADIGM program has begun with significant funding ...
Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...
This debenture was originally issued to provide MYND with the necessary resources to support its progress on a diagnostic ...
Acupuncture. Ketamine infusions. “Electroshock” or electroconvulsive therapy. The existing treatment options for those ...
The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...
Neuronetics ( (STIM) ) has released its Q3 earnings. Here is a breakdown of the information Neuronetics presented to its investors.
Zacks.com on MSN4h
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in FocusXENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD ...
The clinical-stage biopharmaceutical company said it has enough cash to reach the milestones it laid out for 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback